Stocksigma LogoStocksigma Logo

Mankind Pharma Approves Acquisition of 70% Stake in Armed Cell Therapeutics

Mankind Pharma approved an additional investment of up to EUR 45Mn in wholly owned subsidiary Mankind Pharma (Netherlands) B.V., raising its investment

Mankind Pharma Approves Acquisition of 70% Stake in Armed Cell Therapeutics

Mankind Pharma Ltd 路 Others (Uncategorized) 路 16 Oct 2026, 12:53 am

Mankind Pharma Approves Acquisition of 70% Stake in Armed Cell Therapeutics Mankind Pharma approved an additional investment of up to EUR 45Mn in wholly owned subsidiary Mankind Pharma (Netherlands) B.V., raising its investment limit to EUR 50Mn. The subsidiary will acquire a 70% stake in Belgium-based biotech Armed Cell Therapeutics B.V. (ACTx) via an all-cash consideration of EUR 48Mn payable in instalments. ACTx develops next-generation CAR-T cancer therapies, with lead clinical programs targeting non-Hodgkin lymphoma and small cell lung cancer. This strategic transaction marks Mankind's entry into advanced oncology cell therapies.

Original exchange filing (PDF)

More announcements from Mankind Pharma Ltd

All Mankind Pharma Ltd announcements